health

NAFLD Fibrosis Score Calculator

Q: What is the difference between NAFLD and NASH, and how does fibrosis score help distinguish them?

NAFLD is simple steatosis (fat accumulation) without inflammation or fibrosis. NASH (non-alcoholic steatohepatitis) adds active inflammation and hepatocellular injury, conferring higher fibrosis and cirrhosis risk. The fibrosis score does not differentiate NAFLD from NASH directly; it estimates fibrosis risk across the spectrum. Patients with high scores or intermediate scores warrants further investigation (elastography, biopsy) to confirm NASH and guide therapy, as only NASH typically benefits from anti-inflammatory agents.

Q: Can the NAFLD fibrosis score be used in patients with cirrhosis or end-stage liver disease?

The score was derived and validated in cohorts without cirrhosis, so its accuracy declines in advanced disease. Patients with confirmed cirrhosis require specialist hepatology care, ultrasound screening, and portal pressure assessment—not fibrosis scoring. However, scores may be useful in tracking early-stage NAFLD patients longitudinally to detect progression before cirrhosis develops. Once cirrhosis is established, prognostic tools like MELD or Child-Pugh scores become relevant instead.

Q: How often should I recalculate my NAFLD fibrosis score?

Annual reassessment is standard practice in outpatient NAFLD clinics, though intermediate-risk patients or those with changing metabolic status may warrant 6-monthly checks. Stable low-risk scores may permit longer intervals (18–24 months) if accompanied by sustained lifestyle modification and metabolic control. Acute intercurrent illness (infection, hepatotoxic drug exposure) or significant weight change should prompt earlier recalculation to detect score deterioration early.

Q: Does weight loss improve my NAFLD fibrosis score?

Yes. Sustained weight reduction of 5–10% improves hepatic steatosis; losses exceeding 10% improve inflammation and may regress early fibrosis. As weight loss lowers BMI and often improves insulin sensitivity and platelet count, the fibrosis score typically improves. However, fibrosis is partially irreversible, so advanced cirrhotic changes may not fully resolve. Nevertheless, slowing or halting progression is a realistic goal even in advanced stages, making weight management a cornerstone intervention.

Q: Should I get a liver biopsy if my fibrosis score is high?

A high score (>0.676) indicates substantial fibrosis risk and warrants specialist assessment, but biopsy is not automatic. Transient elastography or MR elastography are less invasive alternatives that provide stiffness data; if these align with clinical suspicion, biopsy may be deferred. Biopsy is reserved for diagnostic uncertainty (excluding other diseases) or research settings. Modern practice favours non-invasive imaging; biopsy is now used selectively when diagnosis or treatment decisions hinge on histological detail.

Non-alcoholic fatty liver disease affects roughly one in four people globally, often silently progressing without symptoms. The NAFLD fibrosis score combines routine blood work and clinical metrics to estimate fibrosis risk without the cost and invasiveness of liver biopsy. This calculator helps clinicians and patients understand progression severity and prioritise management strategies for NAFLD complications.

Last updated: April 22, 2026

Creators Adena Benn, BSc

Reviewers Łucja Zaborowska and Małgorzata Koperska

6,126 people find this calculator helpful

Understanding NAFLD and Liver Fibrosis

Non-alcoholic fatty liver disease (NAFLD) involves abnormal lipid accumulation in hepatocytes independent of significant alcohol consumption. Prevalence estimates range from 20–30% in developed nations, with higher rates in patients with obesity and type 2 diabetes. While many remain asymptomatic, progressive cases develop cirrhosis, portal hypertension, and hepatocellular carcinoma.

Fibrosis—the excessive deposition of collagen in response to chronic injury—is the key pathological driver of adverse outcomes. Traditional assessment via liver biopsy carries procedural risks, sampling variability, and substantial cost. Non-invasive scoring systems emerged to stratify fibrosis risk using readily available laboratory and anthropometric data, making population screening and longitudinal monitoring feasible in primary and secondary care settings.

NAFLD Fibrosis Score Formula

The NAFLD fibrosis score integrates six components derived from routine clinical assessment. Age and metabolic markers (BMI, glucose status) reflect disease burden, while liver biochemistry (AST/ALT ratio) and haematological indices (platelet count, albumin) indicate synthetic function and portal pressure.

NFS = −1.675 + (0.037 × age) + (0.094 × BMI)

+ (1.13 × diabetes) + (0.99 × AST/ALT ratio)

− (0.013 × platelet count) − (0.66 × albumin)

age — Patient age in years
BMI — Body mass index in kg/m², calculated from height and weight
diabetes — Presence of impaired fasting glucose or diabetes (1 = yes, 0 = no)
AST/ALT ratio — Aspartate aminotransferase divided by alanine aminotransferase (both in IU/L)
platelet count — Platelet count in 10⁹/L (normal: 150–350)
albumin — Serum albumin level in g/dL (normal: 3.5–5.5)

Score Interpretation and Clinical Implications

The NAFLD fibrosis score stratifies patients into three risk categories:

Score < −1.455: Low probability of advanced fibrosis. Biopsy rarely needed; standard NAFLD lifestyle management is typically sufficient.
Score −1.455 to 0.676: Intermediate zone requiring clinical judgement. Consider repeat testing, specialist referral, or transient elastography for further clarification.
Score > 0.676: High probability of advanced fibrosis (F3–F4). Warrants urgent hepatology evaluation, assessment for complications, and disease-modifying therapy where indicated.

The score's negative predictive value exceeds 90% in published cohorts, reliably excluding advanced fibrosis in low-risk groups. However, intermediate scores necessitate additional diagnostic manoeuvres to avoid both false reassurance and unnecessary invasive testing.

Clinical Considerations and Limitations

Maximise the utility of NAFLD fibrosis scoring by recognising its strengths and constraints:

Serial measurements improve confidence — A single score provides a snapshot. Repeat testing at 6–12 month intervals strengthens prognostic confidence, particularly in intermediate-risk patients. Improved or stable scores may permit longer follow-up intervals, whilst worsening trends prompt specialist evaluation.
Account for confounding conditions — Acute hepatitis, haemolysis, thrombocytopenia from non-hepatic causes, and malnutrition can distort component values. Always contextualise scores within clinical history and exclude alternative liver diseases (viral hepatitis, autoimmune hepatitis, cholestasis).
Platelet count is a powerful fibrosis marker — Mild thrombocytopenia (<150 × 10⁹/L) significantly elevates fibrosis probability independent of other factors. Portal hypertension progressively suppresses bone marrow thrombopoiesis, making platelets both a marker and mechanism of advanced disease.
Consider elastography for intermediate scores — Transient elastography (FibroScan) provides independent stiffness data complementing the fibrosis score. Combined assessment often clarifies intermediate-risk cases, guiding management decisions more reliably than either test alone.

Managing NAFLD Beyond Scoring

Fibrosis score results should inform lifestyle and pharmacological interventions. Sustained weight loss (≥5–10%) improves histology, and randomised trials support intensive metabolic management (glucose optimisation, lipid control, blood pressure reduction) across all fibrosis stages. For advanced fibrosis, pioglitazone and vitamin E show histological benefit in non-diabetic patients, whilst newer agents targeting lipotoxicity and inflammation are in development.

Regular surveillance for hepatocellular carcinoma becomes essential once cirrhosis is confirmed, typically via ultrasound and AFP every 6 months. Addressing comorbidities—particularly diabetes and obesity—is paramount, as their control mitigates fibrosis progression and cardio-metabolic mortality. Patient education about alcohol avoidance and medication safety (hepatotoxic drugs) completes comprehensive NAFLD management.

Frequently Asked Questions

What is the difference between NAFLD and NASH, and how does fibrosis score help distinguish them?

NAFLD is simple steatosis (fat accumulation) without inflammation or fibrosis. NASH (non-alcoholic steatohepatitis) adds active inflammation and hepatocellular injury, conferring higher fibrosis and cirrhosis risk. The fibrosis score does not differentiate NAFLD from NASH directly; it estimates fibrosis risk across the spectrum. Patients with high scores or intermediate scores warrants further investigation (elastography, biopsy) to confirm NASH and guide therapy, as only NASH typically benefits from anti-inflammatory agents.

Can the NAFLD fibrosis score be used in patients with cirrhosis or end-stage liver disease?

The score was derived and validated in cohorts without cirrhosis, so its accuracy declines in advanced disease. Patients with confirmed cirrhosis require specialist hepatology care, ultrasound screening, and portal pressure assessment—not fibrosis scoring. However, scores may be useful in tracking early-stage NAFLD patients longitudinally to detect progression before cirrhosis develops. Once cirrhosis is established, prognostic tools like MELD or Child-Pugh scores become relevant instead.

How often should I recalculate my NAFLD fibrosis score?

Annual reassessment is standard practice in outpatient NAFLD clinics, though intermediate-risk patients or those with changing metabolic status may warrant 6-monthly checks. Stable low-risk scores may permit longer intervals (18–24 months) if accompanied by sustained lifestyle modification and metabolic control. Acute intercurrent illness (infection, hepatotoxic drug exposure) or significant weight change should prompt earlier recalculation to detect score deterioration early.

Does weight loss improve my NAFLD fibrosis score?

Yes. Sustained weight reduction of 5–10% improves hepatic steatosis; losses exceeding 10% improve inflammation and may regress early fibrosis. As weight loss lowers BMI and often improves insulin sensitivity and platelet count, the fibrosis score typically improves. However, fibrosis is partially irreversible, so advanced cirrhotic changes may not fully resolve. Nevertheless, slowing or halting progression is a realistic goal even in advanced stages, making weight management a cornerstone intervention.

Should I get a liver biopsy if my fibrosis score is high?

A high score (>0.676) indicates substantial fibrosis risk and warrants specialist assessment, but biopsy is not automatic. Transient elastography or MR elastography are less invasive alternatives that provide stiffness data; if these align with clinical suspicion, biopsy may be deferred. Biopsy is reserved for diagnostic uncertainty (excluding other diseases) or research settings. Modern practice favours non-invasive imaging; biopsy is now used selectively when diagnosis or treatment decisions hinge on histological detail.

What laboratory errors could falsely elevate my fibrosis score?

Haemolysis during blood draw falsely raises AST and lowers platelet counts, artificially elevating score. Severe acute infection (hepatitis, pneumonia) acutely raises transaminases. Bone marrow disorders or drugs causing thrombocytopenia distort platelet values. Malnutrition or liver synthetic failure lowers albumin. Always request repeat testing if scores change dramatically, and discuss any acute illness or medication changes with your clinician before interpreting results.

More health calculators (see all)

PERC Calculator BED Calculator AFT Calculator Blood Donor Calculator Aleve Dosage Calculator Hematocrit to Hemoglobin Calculator BODE Index Calculator Vitamin A Calculator